Please login to the form below
Gilead
This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.
US government announces first set of drugs subject to Medicare inflation rebates
The 27 products, which all fall under Medicare Part B, include Gilead Sciences’ blood cancer therapies Yescarta and Tecartus, AbbVie’s immunology drug Humira, Seagen’s Padcev for bladder cancer and
Latest news
-
Gilead reports positive real-world evidence for COVID-19 treatment Veklury
Gilead Sciences has reported positive real-world evidence for its COVID-19 treatment, Veklury (remdesivir), demonstrating a reduction in mortality and hospital readmission rates among all patients hospitalised with the virus.
-
Gilead’s Trodelvy shows promise in phase 2 bladder cancer study
Gilead Sciences has reported positive results from a phase 2 trial of its Trop-2 directed antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) in urothelial cancer (UC), the most common type ... Longer-term follow-up results across the three
-
Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
Kite, a Gilead company, has reported positive three-year follow-up results from an ongoing study of its CAR T-cell therapy Tecartus (brexucabtagene autoleucel) in relapsed/refractory B-cell acute
-
Gilead’s Trodelvy approved by FDA for metastatic breast cancer
Gilead Science’s Trodelvy (sacituzumab govitecan-hziy) has been approved by the US Food and Administration (FDA) to treat metastatic breast cancer, the company announced. ... for people with metastatic triple-negative breast cancer,” said Daniel O'Day
-
Kite and Arcellx close multiple myeloma collaboration agreement
Kite, a Gilead Company, and Arcellx have announced the closing of their collaboration agreement to jointly develop and commercialise Arcellx’s late-stage candidate to treat relapsed or refractory multiple myeloma.
More from news
Approximately 226 fully matching, plus 411 partially matching documents found.
Latest Intelligence
-
The state of pharma customer experience
One of those new entrants in the study was UCB. As the highest scoring company, the Belgium-based firm edged a narrow lead over Gilead and Novo Nordisk, who shared a ... On a company level, the three firms leading in the provision of customer experience
-
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
A good example of this is Gilead’s ‘Paintings of Hope’ campaign for metastatic triple-negative breast cancer (mTNBC).
-
Maintaining continuity of care in Ukraine as conflict continues
Gilead Sciences has also been working to address the needs of Ukrainian refugees with HIV.
-
Setting up for success in a post-Brexit, post-pandemic Britain
and running, ahead of our UK marketing authorisation in IBD, through our partnership with Gilead. ... With a focus on inflammatory and fibrotic conditions, we have submitted a marketing application through our partnership with Gilead for a new treatment
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
More from intelligence
Approximately 5 fully matching, plus 56 partially matching documents found.
Latest appointments
-
Lucid Group promotes Clare Reynolds to newly created role
Prior to Lucid, Reynolds served as marketing director, HIV International for Gilead Sciences.
-
New hires at EMA, Gilead and BeiGene
Gilead. Gilead has appointed Mark Genovese (pictured above) as senior vice president, inflammation. ... In this role, Genovese will oversee the clinical development of Gilead’s investigational portfolio of treatments for inflammatory conditions.
-
Ex-BMS exec jumps to Gilead to lead research group
Gilead has also simultaneously announced the promotion of Linda Higgins, who has recently taken on the role of senior vice president and head of external innovation. ... Higgins (pictured right) joined Gilead in 2010 to lead an expansion of the
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
We are very pleased to welcome Sandra Horning to our Board of Directors,” said Daniel O’Day (pictured right), chairman and chief executive officer of Gilead Sciences. ... Sandra’s presence on our board will be a tremendous asset as we enter the
-
New hires at bluebird bio, BioNTech and Provention Bio
He has also held sales, marketing and medical affairs leadership roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences.
More from appointments
Approximately 6 fully matching, plus 21 partially matching documents found.
Latest from PMHub
-
OPEN Health Appoints David P. King as Non-Executive Chairman and Paul Carter as Independent Board Member
In his prior role as head of commercial operations for international markets at Gilead, Mr. ... Carter built out the Gilead commercial infrastructure across 38 countries over eight years.
-
From Vision to Action: Medical Affairs’ Time to Lead is Now – Key Themes and Takeaways From the 2022 Medical Affairs Professional Society (MAPS) Global Annual Meeting
Chris Denove (Amgen), Luca Dezzani (Johnson &Johnson), Jen Prokes (Gilead Sciences), and Pranava Goudan and Sarah Jarvis (ZS Associates). ... External Collaborations in Patient Engagement, presented by Nicholas Brooke (The Synergist), Graeme Johnston
-
IBD Registry wins Communiqué award for COVID-19 tool
The organisation worked closely with partners at the British Society of Gastroenterology and Crohn’s and Colitis UK, with vital support from sponsors including Amgen, Galapagos, Gilead and Tillotts UK.
-
Mednet Group
Clinigen. Crohns and Colitis Department for International Development. Eisai. Gilead. Janssen.
-
90TEN named EMEA Healthcare PR Consultancy of the Year at 2020 SABRE awards
The consultancy was also a finalist for the Best Digital Campaign category for its ‘HIV Garage’ programme for Gilead Sciences.
More from PMHub
Approximately 1 fully matching, plus 15 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Janssen’s single tablet combination shows promise in phase 3 PAH study
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- How to make sure your adverts for clinical trials are compliant
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
